Advertisement!
Author Information Pack
Editorial Board
Submit article
Special Issue
Editor's selection process
Join as Reviewer/Editor
List of Reviewer
Indexing Information
Most popular articles
Purchase Single Articles
Archive
Free Online Access
Current Issue
Recommend this journal to your library
Advertiser
Accepted Articles
Search Articles
Email Alerts
FAQ
Contact Us
Indian Journal of Maternal-Fetal & Neonatal Medicine

Volume  5, Issue 1, January - June 2018, Pages 13-16
 

Original Article

Efficacy of Ormeloxifene in the Management of Dysfunctional Uterine Bleeding

Swati Gett1, Shruti Singh2

1,2Senior Resident, Dept. of Obstetrics and Gynecology, Kasturba Hospital, Delhi- 110006, India.

Choose an option to locate / access this Article:
90 days Access
Check if you have access through your login credentials.        PDF      |
|

Open Access: View PDF

DOI: DOI: http://dx.doi.org/10.21088/ijmfnm.2347.999X.5118.2

Abstract

Introduction: Dysfunctional Uterine Bleeding is the most common cause of abnormal vaginal bleeding during a woman’s reproductive years. ‘Ormeloxifene’ a nonsteroidal selective estrogen receptor modulator (SERM), is currently undergoing clinical evaluation for the treatment of heavy menstrual bleeding. It normalizes the bleeding from the uterine cavity by regularizing the expression of estrogen receptors on the endometrium.

Aim and Objectives: To study the efficacy of Ormeloxifene in the management of dysfunctional uterine bleeding.

Material and Methods: A total of 50 women between 20 to 50 years of age presenting with abnormal or dysfunctional uterine bleeding during a period of one year included in the study. During each visit a detailed menstrual history was taken and PBAC score was calculated. All patients of DUB under study treated with Ormeloxifene and the treatment outcome measured.

Results: Among a total of 50 patients, there were 25 (50%) patients belonged to 31-40 years age group with 37.9 years to be a mean of all ages. The mean Hb level recorded was 7.3gm%. The mean PBAC score prior to treatment was 274 which was found to be decreased upto 91.7 after a treatment of 3 months with Ormeloxifene.

Conclusions: DUB is considered to be caused because of the hormonal imbalance, eventually leading to hyperestrogenic state, which can be quite successfully treated by the medical management, like Ormeloxifene.

Keywords: Dysfunctional Uterine Bleeding. 


Corresponding Author : Swati Gett, Senior Resident, Dept. of Obstetrics and Gynecology, Kasturba Hospital, Delhi- 110006, India.